Health Care • Biotechnology: Pharmaceutical Preparations
$6.53 ▲ +0.19
(+2.92%)
MKT CAP: $29.9M • VOL: 58.3K
52W L $2 52W H $16
ROARABLE / RQD
D- • 39/100
PIOTROSKI
2 / 9
NXTC // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$57.6M | -$59.7M | -$67.6M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$55.8M | -$55.7M | -$62.7M |
| EBITDA (Normalized) | — | -$59.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$49.6M | -$40.8M | -$53.0M |
| Capital Expenditures (CapEx) | — | $474.0K | — |
| Free Cash Flow (FCF) | -$49.6M | -$41.3M | -$53.0M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $26.0M | $27.7M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $34.9M | $65.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NXTC.